Grandeur Peak Global Advisors LLC Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Grandeur Peak Global Advisors LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 96.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,325 shares of the medical device company’s stock after buying an additional 650 shares during the quarter. Grandeur Peak Global Advisors LLC’s holdings in DexCom were worth $476,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of DXCM. Lone Pine Capital LLC raised its holdings in shares of DexCom by 389.7% in the 4th quarter. Lone Pine Capital LLC now owns 2,267,809 shares of the medical device company’s stock valued at $838,454,000 after buying an additional 1,804,722 shares during the period. Janus Henderson Group PLC increased its holdings in DexCom by 201.4% during the 1st quarter. Janus Henderson Group PLC now owns 1,868,977 shares of the medical device company’s stock worth $671,700,000 after purchasing an additional 1,248,830 shares during the period. Norges Bank purchased a new stake in DexCom during the 4th quarter worth about $283,445,000. Sands Capital Management LLC increased its holdings in DexCom by 28.2% during the 1st quarter. Sands Capital Management LLC now owns 2,936,502 shares of the medical device company’s stock worth $1,055,349,000 after purchasing an additional 645,568 shares during the period. Finally, Artisan Partners Limited Partnership increased its holdings in DexCom by 29.8% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,967,829 shares of the medical device company’s stock worth $707,218,000 after purchasing an additional 451,362 shares during the period. Hedge funds and other institutional investors own 93.48% of the company’s stock.

In other news, SVP Sumi Shrishrimal sold 1,461 shares of the firm’s stock in a transaction that occurred on Tuesday, May 25th. The stock was sold at an average price of $354.79, for a total value of $518,348.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Steven Robert Pacelli sold 1,079 shares of the firm’s stock in a transaction that occurred on Friday, April 23rd. The shares were sold at an average price of $410.31, for a total value of $442,724.49. The disclosure for this sale can be found here. Insiders sold a total of 67,603 shares of company stock valued at $27,159,356 over the last three months. Insiders own 0.52% of the company’s stock.

Several brokerages have weighed in on DXCM. Citigroup upped their price target on DexCom from $480.00 to $488.00 in a report on Friday, April 30th. Atlantic Securities began coverage on DexCom in a report on Thursday, April 15th. They set an “overweight” rating and a $438.00 price target on the stock. Wells Fargo & Company upgraded DexCom from an “underweight” rating to an “equal weight” rating and set a $380.00 price target on the stock in a report on Friday, May 28th. Cowen dropped their price objective on DexCom from $540.00 to $525.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Canaccord Genuity increased their price objective on DexCom from $445.00 to $455.00 and gave the company a “buy” rating in a report on Friday, April 30th. Two investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $466.00.

DexCom stock traded up $2.11 during mid-day trading on Thursday, reaching $449.09. 839 shares of the company were exchanged, compared to its average volume of 773,000. The company has a current ratio of 5.70, a quick ratio of 5.22 and a debt-to-equity ratio of 0.89. The stock has a 50-day moving average price of $400.94. The stock has a market capitalization of $43.43 billion, a price-to-earnings ratio of 88.08 and a beta of 0.79. DexCom, Inc. has a twelve month low of $305.63 and a twelve month high of $456.23.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 29th. The medical device company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.31 by $0.02. The business had revenue of $505.00 million during the quarter, compared to analysts’ expectations of $482.67 million. DexCom had a return on equity of 17.86% and a net margin of 25.36%. Sell-side analysts predict that DexCom, Inc. will post 2.15 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.

Recommended Story: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.